Qualigen Therapeutics, INC 10-Q quarterly reports

AIxCrypto Holdings reported substantial net losses and significant cash burn, raising serious concerns about its ability to continue as a going concern, despite a strategic pivot towards AI and digital assets.

AIxCrypto Holdings reports a significant strategic pivot towards RWA tokenization and Embodied AI, with Q1 2026 results reflecting increased operational costs and a substantial net loss.

Qualigen Therapeutics, Inc. reported a significant capital raise of $41 million, primarily for new cryptocurrency treasury operations, despite ongoing operational losses and substantial doubt about its ability to continue as a going concern.

Qualigen Therapeutics reports significant losses and negative cash flow, raising substantial doubt about its ability to continue as a going concern, despite recent capital raises.

Qualigen Therapeutics, Inc. reported a significant increase in net loss and a drastic reduction in cash reserves for Q1 2025, raising substantial doubt about its ability to continue as a going concern, despite ongoing efforts to raise capital.

Qualigen Therapeutics reports a net loss of $1.8 million for Q3 2024, with ongoing concerns about its ability to continue as a going concern.

Qualigen Therapeutics reported its Q2 2024 results, showing a net loss and ongoing financial challenges, while advancing its clinical-stage therapeutic program.

Qualigen Therapeutics reported a net loss of $2.03 million for Q1 2024 and faces substantial doubt about its ability to continue as a going concern.